Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis
BG Schimmelmann, P Conus, S Cotton, S Kupferschmid, PD McGorry, M Lambert
European Psychiatry | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | Published : 2012
Eli Lilly Australia funded the assessment of files on a subgroup of this cohort treated with olanzapine and risperidone.The acquisition of data was in part supported by the Colonial Foundation, National Health and Medical Research Council and Eli Lilly Australia. Drs. Schimmelmann, Conus, McGorry, and Lambert have received research funding from and/or served as paid speaker for Eli Lilly.Dr. Philippe Conus is supported by the Leenaards Foundation, Switzerland. Dr Sue Cotton is supported by the Ronald Phillip Griffith Fellowship, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne.